<DOC>
	<DOCNO>NCT00037596</DOCNO>
	<brief_summary>The primary objective ) establish maximum tolerated dose gemtuzumab ozogamicin combination cytarabine b ) ass safety gemtuzumab ozogamicin give concurrently cytarabine .</brief_summary>
	<brief_title>Study Evaluating Gemtuzumab Ozogamicin Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<criteria>Morphologic diagnosis AML bone marrow aspirate biopsy Flow cytometry , perform study site , must demonstrate patient AML CD33+ , base local laboratory criterion Age 18 year old relapse refractory patient Phase I study Patients de novo AML M3 subtype AML follow antecedent hematologic disorder ( myelodysplasia myeloproliferation ) &gt; 2 month duration AML secondary exposure chemotherapy radiation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>